Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Boulanger
Jean-Martin
JM
Hill
Michael D
MD
D000179:Acrylates / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000473:pathology; D003627:Data Interpretation, Statistical; D004232:Diuretics / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007388:Internal Medicine / Q000379:methods; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D009017:Morbidity; D009462:Neurology / Q000379:methods; D009568:Nitrendipine / Q000494:pharmacology*; D011446:Prospective Studies; D020521:Stroke / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D013876:Thiophenes / Q000494:pharmacology*
D000179:Acrylates; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D009568:Nitrendipine